Blake Borgeson, Director at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 40,108 shares at $10.12 ($406K) on 2024-05-14, disclosed to the SEC on 2024-05-16.
Scheduled sale ($406k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.12 | 20,054 | $203K | 50.0% |
| 2 | $10.12 | 20,054 | $203K | 50.0% |
| Total | $10.12 avg | 40,108 | $406K | 100% |
| Filing → |
| RXRX | SELL | 2026-08-06 | $98K | — | Filing → |
| RXRX | SELL | 2026-07-09 | $159K | — | Filing → |
| RXRX | SELL | 2026-06-04 | $110K | — | Filing → |